VT-11CR for Pancreatic Cancer

Our primary strategy with VT-11CR is aimed at patients with non-resectable pancreatic cancer. This type of pancreatic cancer represents approximately 80% of the pancreatic cancer cases in the US, EU and Japan.  We are initially focused on the treatment of  patients with non-resectable metastatic pancreatic cancer receiving  nab-paclitaxel plus gemcitabine.

Despite advances in the treatment of these patients,  most will progress on nab-paclitaxel plus gemcitabine with an expected survival of less than one year.  We believe that our strategy to damp tumor-promoting inflammation, restore immune surveillance and improve treatment tolerance with VT-11CR may significantly improve outcomes for pancreatic cancer patients.